Table II.
Clinical outcomes.
| Variables | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| Regions of vertebral metastases | C5-Th2 | Th4–10 | Th4–10 | C5-Th6 |
| Preoperative Tokuhashi score | 9 | 8 | 7 | 9 |
| Preoperative Tomita score | 8 | 6 | 8 | 6 |
| Frankel grade (before→after surgery) | C→D | C→D | C→D | C→E |
| ECOG PS (before→after surgery) | 2→1 | 2→1 | 2→1 | 2→1 |
| Postoperative therapy | Chemotherapy | Chemotherapy | Chemotherapy | Chemotherapy |
| EGFR-TKI | EGFR-TKI | Radiation | EGFR-TKI | |
| Radiation | Bisphosphonate | Bisphosphonate | Bisphosphonate | |
| Predicted prognosis by Tokuhashi score (months) | <12 | <6 | <6 | <12 |
| Postoperative paralysis-free period (months) | 17 | 43 | 40 | 42 |
| Postoperative survival time (months) | 22 | 44 | 40 | 43 |
PS, performance status; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status.